Regulatory21 Oct 2026 · Tue evening
SUNPHARMASun Pharma
Sun Pharma's Unloxcyt gets NCCN 2A preferred status for locally advanced skin cancer
Sun Pharma said Unloxcyt (cosibelimab-ipdl) now holds a Category 2A preferred designation in the US NCCN guidelines for locally advanced cutaneous squamous cell carcinoma.
- Sector
- Pharmaceuticals
What happened
- Unloxcyt has a Category 2A preferred designation in the National Comprehensive Cancer Network guidelines for patients with locally advanced cutaneous squamous cell carcinoma who cannot have curative surgery or radiation, according to Whalesbook and Sahi.
- Sahi noted that Unloxcyt already held a Category 2A designation in metastatic disease, assigned in 2025.
- Whalesbook listed the pivotal study's results: an objective response rate of 55%, a complete response rate of 26%, a median duration of response not reached at follow-up beyond 24 months, and high-grade immune-mediated adverse events in under 1% of patients.
- Whalesbook published the news at 5:35 PM on Tuesday and Sahi at 7:03 AM on Wednesday. Sahi said the Innovative Medicines segment made up 22% of Sun Pharma's consolidated revenue in FY26.
- The shares closed at ₹1,743 on Monday, down 0.90%, per Zerodha Kite; NSE was shut on Tuesday.
Why it matters
Sahi said NCCN guidelines influence prescribing and insurance coverage decisions in the US; the 22% share of revenue it cites is for the whole Innovative Medicines segment, not Unloxcyt.
Good to know: NCCN is the National Comprehensive Cancer Network, a US alliance of cancer centres that publishes treatment guidelines. Category 2A means the recommendation rests on lower-level evidence but has uniform consensus among the panel.
Key facts
- Designation
- NCCN Category 2A, preferred, locally advanced cutaneous squamous cell carcinoma
- Objective response rate
- 55%, per Whalesbook
- Complete response rate
- 26%, per Whalesbook
- Innovative Medicines share of FY26 revenue
- 22%, per Sahi
Read the source
This is a summary of public news about Sun Pharma, for information only. It is not a recommendation to buy, sell or hold SUNPHARMA.
Sun Pharma in the news before
- 2 NOV 2026 · EVENING · RESULTSSun Pharma's Q2 profit falls 36% to ₹1,989 crore after a ₹1,269 crore one-time loss
- 14 OCT 2026 · EVENING · CORPORATE ACTIONSSun Pharma's board approves up to ₹10,000 crore of debentures; a director resigns
- 29 SEP 2026 · DEALS & FUNDINGSun Pharma licenses cholesterol drug lerodalcibep for markets outside the US and China